ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1167

Phenotypical Features of Patients with Rheumatologic Manifestations of Common Variable Immunodeficiency

MARIA GUTIERREZ1, Kathleen E. Sullivan2, Ramsay Fuleihan3 and Clifton O. Bingham III4, 1Pediatrics, Johns Hopkins University, BALTIMORE, MD, 2Pediatrics, University of Pennsylvania, Philadelphia, PA, 3Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 4Rheumatology, Johns Hopkins University, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmunity and immunodeficiency, CVID, Immune Dysregulation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with common variable immunodeficiency (CVID) have a higher incidence of rheumatologic disorders. To delineate this clinical association, we investigated the phenotypical features of patients with CVID affected by these conditions.

Methods:

We conducted a retrospective analysis of 870 pediatric and adult patients with CVID included in the United States Immunodeficiency Network (USIDNET) registry. Outcomes included clinical characteristics (age, gender, ethnicity, rheumatologic diagnosis, comorbidities) and basic immunophenotype (immunoglobulin levels, T- and B- cell counts) in patients with rheumatologic disorders compared with those with non-inflammatory CVID. Demographic and clinical data were compared using chi-square, Fisher’s exact or Wilcoxon-Mann-Whitney tests. For immunological variables, Generalized Estimating Equations (GEE) regression models were built to evaluate the relationship between IgA, IgM, CD19+ B-cell counts and CD4/CD8 ratios and CVID-associated rheumatologic disorders.

Results:

Physician-reported rheumatic diseases were present in 5.9% of patients with CVID (n=51) included in the registry. Although CVID affects both sexes equally, there were more females (3.3:1 female to male ratio) in the rheumatic disease group (p<0.05). Specific disorders included: inflammatory arthritis (n=18), Sjogren’s syndrome (n=11), SLE (n=8), Raynaud’s syndrome (n=8), medium and small vessel vasculitis (n=8), MCTD (n=3), other (n=5). There were no significant differences in the frequency of other CVID complications such as bronchiectasis between the two groups (p>0.05). Additionally, no significant differences in immunoglobulin levels (IgA and IgM), CD19+ B-cells counts or CD4/CD8 ratio were detected.

Conclusion:

These results highlight the coexistence of primary antibody disorders and systemic autoimmune diseases. Importantly, hypergammaglobulinemic, autoantibody-associated disorders such as Sjogren’s syndrome and SLE were among the most common, demonstrating that they can occur even in the setting of a primary antibody deficiency. Basic immunophenotypical parameters demonstrated no significant differences, although characteristics such as specific T- and B-cell subpopulations were not evaluated. Finally, the female predominance in the rheumatic disease group, brings into question whether sex-related factors may play a role in the development of certain CVID manifestations. This study has several limitations, namely the retrospective nature of the analysis, variable amounts of missing data and lack of confirmation of rheumatic diagnosis using current classification data. Nonetheless, these findings should raise awareness for primary antibody immunodeficiencies among patients with rheumatic disorders. Delineating the link between systemic autoimmunity and humoral immunodeficiencies can also provide novel insights into the immune abnormalities underlying these related conditions.


Disclosure: M. GUTIERREZ, None; K. E. Sullivan, None; R. Fuleihan, None; C. O. Bingham III, BMS, 2,BMS, 5.

To cite this abstract in AMA style:

GUTIERREZ M, Sullivan KE, Fuleihan R, Bingham III CO. Phenotypical Features of Patients with Rheumatologic Manifestations of Common Variable Immunodeficiency [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/phenotypical-features-of-patients-with-rheumatologic-manifestations-of-common-variable-immunodeficiency/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phenotypical-features-of-patients-with-rheumatologic-manifestations-of-common-variable-immunodeficiency/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology